CMS certification 103304
Nemours Childrens Hospital, Florida
6535 Nemours Pkwy, Orlando, FL 32827
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
184 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 33 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 48 |
| Physician Assistant | 27 |
| Pediatric Radiology | 8 |
| Clinical | 7 |
| Nurse Practitioner | 7 |
| Genetic Counselor, MS | 6 |
| Pediatric Critical Care Medicine | 6 |
| Pediatric Emergency Medicine | 6 |
| Pediatric Anesthesiology | 5 |
| Pediatrics, Critical Care | 5 |
| Audiologist | 3 |
| Clinical Child & Adolescent | 3 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2022 $872,165
- 2023 $865,821
- 2024 $1.2M
- 2025 $1.6M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Royalties and licensing fees | $200,000 | 2 |
| Speaking, teaching and other services | $36,150 | 43 |
| Space rental and facility fees | $31,975 | 10 |
| Medical devices and supplies on long-term loan | $9,090 | 1 |
| Gifts | $1,950 | 1 |
| Consulting fees | $1,500 | 2 |
| Education | $1,500 | 1 |
| Grants | $1,500 | 2 |
| Debt forgiveness | $79 | 1 |
| Charitable contributions | $50 | 2 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| BioMarin Pharmaceutical Inc. | $327,173 | 68 |
| Masimo Corporation | $200,000 | 2 |
| Abbvie INC. | $171,595 | 46 |
| Ultragenyx Pharmaceutical Inc. | $153,700 | 59 |
| Hoffmann-La Roche Limited | $117,674 | 41 |
| AstraZeneca UK Limited | $100,879 | 1 |
| Immedica Pharma US, Inc. | $84,757 | 16 |
| Takeda Pharmaceuticals U.S.A., Inc. | $52,707 | 7 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 admini… AstraZeneca UK Limited | $100,879 |
| UX143-CL301 Ultragenyx Pharmaceutical Inc. | $90,681 |
| A Phase 3, Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis… Immedica Pharma US, Inc. · NCT05604170 | $84,757 |
| BMN 111-210 BioMarin Pharmaceutical Inc. | $78,140 |
| RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY Hoffmann-La Roche Limited | $74,780 |
| A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia BioMarin Pharmaceutical Inc. | $69,498 |
| UX143-CL314 Ultragenyx Pharmaceutical Inc. | $63,019 |
| BMN 111-211 BioMarin Pharmaceutical Inc. | $62,994 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Nemours Childrens Hospital, Florida
Does Nemours Childrens Hospital, Florida have an emergency room?
Yes. CMS lists emergency services at Nemours Childrens Hospital, Florida.
Does Nemours Childrens Hospital, Florida receive money from drug and device companies?
Drug and device makers reported $1.6M in payments to Nemours Childrens Hospital, Florida for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.